Latest news with #OKYO
Associated Press
3 days ago
- Business
- Associated Press
Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited
Raising Price Target Due to Fundamental Drivers BALTIMORE, MD / ACCESS Newswire / June 11, 2025 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research update on OKYO Pharma Limited (NASDAQ:OKYO), an emerging player in the fast-growing ophthalmic drugs segment. The Goldman report carries a price target. To view the new research update, previous OKYO reports, along with disclosures and disclaimers, or to download the update in its entirety, please visit: OKYO Pharma Limited Is a clinical stage bio-pharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and dry eye disease (DED), with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO's lead drug candidate successfully completed a 240-patient Phase 2 trial in DED patients and completed a 17-patient Phase 2 trial in NCP patients. OKYO elected to lose the trial early. The implications of the early trial completion plus desire to immediately analyze clinical results and release top-line data in 3Q25 suggest potential, immediate outcomes, pending positive top-line results, in our view. In the Opportunity Research update, analyst Rob Goldman reviews recent share performance, clinical achievements, upcoming milestones and why recent and pending events prompted us to raise our price target for OKYO. OKYO: A Stellar Performer Goldman commented, 'Since our January 2025 report, OKYO's shares have essentially doubled, along with a doubling of average daily volume. Plus, the shares have set a new 52-week high.' Early Closure of Phase 2 Trial is a Major Plus 'In our view, share price rise has been driven by fundamental developments, including the receipt of Fast Track designation for its lead candidate urcosimod, and the unexpected early completion of its Phase 2 trial,' noted Goldman. 'The early trial closure potentially shortens OKYO's development pathway as top-line results are slated to be released in 3Q25, months earlier than originally forecasted. A key takeaway is that the acceleration of the release of potentially positive top-line Phase 2 data should also shorten the time that we believe these shares would take to reach our upgraded, $8.00 price target, up from $5.00, previously.' Substantial Potential Opportunity 'As a first-mover that has the potential to publish favorable results for a debilitating condition that has a serious unmet need, and represents a multi-billion-dollar market, we believe these shares could reach new heights. Furthermore, we believe that given the M&A activity in the ocular space, a deal with a partner could occur, and that the Company would benefit from the aforementioned re-valuation of these shares,' concluded Goldman. About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co. This press release contains excerpts of our most recently published company report on OKYO Pharma Limited ('The Company'). The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from OKYO Pharma Limited. The information includes authorized press releases or legal disclosures made in their filings with the U.S. Securities and Exchange Commission Separate from the factual content of our update about the Company, we may from time to time include our own opinions about the Company, its business, markets, and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, sector or industry snapshot, podcast interview, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. To download this research update visit Goldman Small Cap Research did not receive any compensation for this update. In January 2025, Goldman Small Cap Research was compensated by the Company in the amount of $4000 for a research report production and distribution, including a press release. In 2023, Goldman Small Cap Research (GSCR) was compensated by a third party (TraDigital Marketing Group, Inc.) in the amount of $4000 for research report production and a press release. SOURCE: Goldman Small Cap Research press release
Associated Press
19-05-2025
- Business
- Associated Press
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit
LONDON and NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases, announced that its CEO, Gary S. Jacob, Ph.D., will be giving an oral presentation at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA on May 22, 2025. Dr. Jacob's presentation will cover the development of urcosimod, OKYO's lead clinical drug candidate, to treat neuropathic corneal pain (NCP) which is a debilitating condition affecting many tens of thousands worldwide, and is characterized by chronic, severe eye discomfort. Presentation Information: Event: 4th Annual GPCRs-Targeted Drug Discovery Summit Presenter: Dr. Gary S. Jacob, CEO of OKYO Pharma Presentation Title: Clinical Development of Urcosimod, Targeting CMKLR1 (ChemR23), to Treat Neuropathic Corneal Pain Date: Thursday, May 22, 2025 Location: Revere Hotel Boston Common, Boston, MA About Neuropathic Corneal Pain (NCP) NCP is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause of NCP is unknown but is thought to result from nerve damage to the cornea combined with inflammation. NCP, which can exhibit as a severe, chronic, debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated, with limited success, by various topical and systemic treatments in an off-label fashion. About Urcosimod (formerly called OK-101) Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the residence time of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and is presently being evaluated in a just-completed randomized, placebo-controlled, double-masked Phase 2 trial involving 17 neuropathic corneal pain patients. About OKYO OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and ocular diseases. In addition to the completed Phase 2 trial of urcosimod to treat dry eye disease patients, OKYO is also currently evaluating urcosimod to treat neuropathic corneal pain patients in a Phase 2 trial. For further information, please visit Enquiries:
